Visual rating scale for assessment of the cingulate island sign in the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease

We investigated diagnostic characteristics of spatial covariance analysis (SCA) of FDG-PET and HMPAO-SPECT scans in the differential diagnosis of dementia with Lewy bodies (DLB) and Alzheimer's disease (AD), in comparison with visual ratings and region of interest (ROI) analysis. Sixty-seven patients (DLB 29, AD 38) had both HMPAO-SPECT and FDG-PET scans. Spatial covariance patterns were used to separate AD and DLB in an initial derivation group (DLB n=15, AD n=19), before being forward applied to an independent group (DLB n=14, AD n=19). Visual ratings were by consensus, with ROI analysis utilising medial occipital/medial temporal uptake ratios. SCA of HMPAO-SPECT performed poorly (AUC 0.59 +/- 0.10), whilst SCA of FDG-PET (AUC 0.83 +/- 0.07) was significantly better. For FDG-PET, SCA showed similar diagnostic performance to ROI analysis (AUC 0.84 +/- 0.08) and visual rating (AUC 0.82 +/- 0.08). In contrast to ROI analysis, there was little concordance between SCA and visual ratings of FDG-PET scans. We conclude that SCA of FDG-PET outperforms that of HMPAO-SPECT and performed similarly to other analytical approaches, with the potential to improve with larger derivation groups. Compared to visual rating, SCA of FDG-PET relies on different sources of group variance to separate DLB from AD.

Download Full-text

Plasma butyrylcholinesterase activity: a possible biomarker for differential diagnosis between Alzheimer's disease and dementia with Lewy bodies?

International Journal of Neuroscience ◽

10.1080/00207454.2017.1329203 ◽

2017 ◽

Vol 127 (12) ◽

pp. 1082-1086 ◽

Cited By ~ 5

Author(s):

N. D. Josviak ◽

M. S. Batistela ◽

R. K. M. Souza ◽

N. R. Wegner ◽

G. F. Bono ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Differential Diagnosis ◽

Dementia With Lewy Bodies ◽

Lewy Bodies ◽

Butyrylcholinesterase Activity

Download Full-text

Assessment of genetic risk for improved clinical-neuropathological correlations

Acta Neuropathologica Communications ◽

10.1186/s40478-020-01033-1 ◽

2020 ◽

Vol 8 (1) ◽

Author(s):

Barbara E. Spencer ◽

Robin G. Jennings ◽

Chun C. Fan ◽

James B. Brewer

Keyword(s):

Alzheimer’S Disease ◽

Parkinson’S Disease ◽

Alzheimer's Disease ◽

Parkinson's Disease ◽

Genetic Risk ◽

Dementia With Lewy Bodies ◽

Lewy Bodies ◽

Pathological Diagnosis ◽

Polygenic Score ◽

Diagnosis Of Dementia

Abstract In the clinical diagnosis of dementia with Lewy bodies, distinction from Alzheimer’s disease is suboptimal and complicated by shared genetic risk factors and frequent co-pathology. In the present study we tested the ability of polygenic scores for Alzheimer’s disease, dementia with Lewy bodies, and Parkinson’s disease to differentiate individuals in a 2713-participant, pathologically defined sample. A dementia with Lewy bodies polygenic score that excluded apolipoprotein E due to its overlap with Alzheimer’s disease risk was specifically associated with at least limbic (transitional) Lewy-related pathology and a pathological diagnosis of dementia with Lewy bodies. An Alzheimer’s disease polygenic score was associated with neuritic plaques and neurofibrillary tangles but not Lewy-related pathology, and was most strongly associated with an Alzheimer’s pathological diagnosis. Our results indicate that an assessment of genetic risk may be useful to clinically distinguish between Alzheimer’s disease and dementia with Lewy bodies. Notably, we found no association with a Parkinson’s disease polygenic score, which aligns with evidence that dementia with Lewy bodies has a distinct genetic signature that can be exploited to improve clinical diagnoses.

Download Full-text